procedures in 11% of visits. African Americans, females, and young adults had higher numbers of visits for HS. Conclusions: Our data showing a maximum of 0.06% of the population being treated for HS in a given year are consistent with the low estimates of HS prevalence. Compared to the current prescribing patterns, the more frequent prescription of biologics and systemic treatments may yield better outcomes.
Introduction
Hidradenitis suppurativa (HS) is a condition characterized by lesions affecting the skin with apocrine glands [1] . Treatments may include topical or oral antibiotics, topical or systemic steroids, isotretinoin, antiandrogens in some female patients, cyclosporine, and tumor necrosis factor inhibitors as well as surgery and laser therapy [1] . Few randomized controlled trials have been performed to evaluate the efficacy of HS therapies, although etanercept, adalimumab, and infliximab have all been tested in randomized controlled trials, with mixed results [2] [3] [4] . Although there are no official guidelines for treating HS, antibiotics tend to be preferred for mild to mod-erate cases, while more severe cases may be treated with any of several systemic therapies such as steroids and biologics [1] . This study attempts to present nationally representative data to demonstrate how frequently HS occurs in specific groups and how it is currently managed.
Methods
The National Ambulatory Medical Care Survey (NAMCS), conducted by the National Center for Health Statistics (NCHS), is designed to meet the need for objective, reliable information about the provision and use of ambulatory medical care services in the United States. Findings are based on a stratified random sample of visits to nonfederally employed office-based physicians who are primarily engaged in direct patient care. Physicians in the specialties of anesthesiology, pathology, and radiology, which are not normally involved in direct patient care, are excluded from the survey. The survey was conducted annually from 1973 to 1981, in 1985, and annually since 1989.
Each physician is randomly assigned to a 1-week reporting period in which data for a systematic random sample of visits are recorded by the physician, office staff, or an NCHS survey staff member on an encounter form provided for that purpose. Data are obtained on patients' symptoms, physicians' diagnoses, medications ordered or provided, and the demographic characteristics of patients and services provided, including information on diagnostic procedures, patient management, and planned future treatment. Survey weights are applied to estimate visit counts. Estimated quantities of visits were rounded to the same number of significant digits as in the unweighted counts.
For the current study, we searched the 1990-2009 NAMCS for visits with a primary, secondary, or tertiary diagnosis of HS (ICD-9 code 705.83). Frequency tables were produced for demographic data, reasons for visit, medications, medication classes, procedures, and comorbidities associated with HS. Drug mentions include medications administered, prescribed, dispensed, or discussed at the visit. Linear regressions (SAS PROC SURVEYREG) were used to analyze trends over time in demographics and the treatment of HS. All data analyses were performed with SAS 9.1.3 (SAS Institute, Cary, N.C., USA) and Stata 12 (Stata, College Station, Tex., USA). To calculate estimates for the number of visits per 100,000 population of each race and ethnicity, we used data from the 2000 US Census on the population for each race and ethnicity.
The MarketScan Medicaid database is a family of databases containing individual-level health care claims, lab test results, and hospital discharge information from large employers, managed care organizations, hospitals, and public health insurance programs, such as Medicare and Medicaid. For this study, the dataset for Medicaid enrollees was used. Overall, the database covers 100 million patients in the United States and captures the full continuum of care in all health care settings, including physician office visits, hospital admissions, carve-out care, as well as retail, mail order, and specialty pharmacies. Patients with at least one outpatient visit during the time period of 2003-2007 were included in this study. We identified the date of the first diagnosis of HS for each patient, and only the medication records after the first diagnosis of HS were included in the analysis.
Results
In the NAMCS, there were an estimated 3,280,000 visits (95% CI: 2,560,000-4,000,000; fig. 1 ; table 1 ) over the period 1990-2009 with a diagnosis of HS (ICD-9 code 705.83). Of these, HS was the primary diagnosis for 2,610,000, the secondary diagnosis for 500,000, and the tertiary diagnosis for 160,000. It was the sole diagnosis for 1,820,000 or 55.5% of the HS visits. On an annual basis, there were an average of 164,000 HS visits per year (95% CI: 128,000-200,000). In the MarketScan Medicaid dataset, there were 17,270 patients with a diagnosis of HS over the 5-year period from 2003 to 2007. Of these, 15,959 had a record of claims after their first HS diagnosis.
The leading reasons for visit among the patients with a diagnosis of HS in the NAMCS included carbuncle/furuncle/boil/cellulitis/abscess not elsewhere classified, other diseases of the skin (including HS, as there is no In the NAMCS, HS was most often treated with a medication (74% of visits) and much less often with a procedure (11%; table 2 ). The greatest number of patients received antibiotics, well ahead of pain medications and corticosteroids ( table 3 ; fig. 2 , 3 ). The systemic retinoid isotretinoin was also in the top ten.
Systemic steroids prescribed included prednisone (0.4% of visits), methylprednisolone (0.6%), and dexamethasone (0.1%). No patients were observed to have been treated with tumor necrosis factor inhibitors (etanercept, adalimumab, or infliximab), or with the systemic treatments methotrexate, acitretin, or cyclosporine.
Although the sample size was not large enough to achieve statistical significance, patients appeared to re-0 Year 100,000 200,000 300,000 400,000 500,000 600,000 Visits 1 9 9 3 1 9 9 2 1 9 9 1 1 9 9 0 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 68 ceive combination therapy with a medication and a procedure more often when visiting dermatologists (15 vs. 6%). On the other hand, nondermatologists appeared more likely to give neither medication nor procedural treatment (28 vs. 2%).
When a procedure was done in the NAMCS, it was most often local excision or destruction of a skin lesion, or another incision with drainage of skin ( table 4 ) .
In MarketScan, the leading medications also included pain relievers and antibiotics, led by hydrocodone/acet- Leading medication classes prescribed for the diagnosis of HS. Antibiotics were prescribed in more than half of HS visits in the NAMCS. Ten categories were prescribed in at least 1% of visits, and pain relievers and topical steroids were the only other categories prescribed in more than 10% of visits. Leading medication classes prescribed for the sole diagnosis of HS. Antibiotics were by far the most common treatments prescribed for visits with a sole diagnosis of HS in the NAMCS. Seven categories were prescribed in at least 1% of visits. Antibiotics were by far the leading treatment listed in NAMCS visits for HS, whereas hydrocodone/acetamino-phen and ibuprofen were near the top of the list of Mar-ketScan medications for HS. Since MarketScan records the prescriptions actually filled, while NAMCS records what was prescribed at the office visit, it may be that prescriptions for pain medications are more likely to be filled than those for antibiotics.
Complicating factors for comparison of the two datasets include sampling of office visits in NAMCS versus records of claims in MarketScan; tracking individual patients over time in MarketScan but not in NAMCS; analysis of only Medicaid patients in MarketScan versus patients with any payer in NAMCS, and the fact that Mar-ketScan captures medications prescribed in emergency departments while NAMCS does not.
Leading procedures related to HS in MarketScan included incision and drainage of abscess, excision of axillary skin for hidradenitis with simple/intermediate repair, incision and drainage of abscess (multiple), and excision of axillary skin for hidradenitis with complex repair ( table 6 ).
In NAMCS patients with HS, the leading comorbidities ( fig. 4 ) included a variety of dermatologic conditions, such as warts and acne, as well as nondermatologic conditions such as diabetes and hypertension.
Patient visits for HS in the NAMCS showed a female:male ratio of about 2: 1. The estimated percentage of female patients was 67.4% (95% CI: 56.3-78.5). There was no statistically significant trend over time in gender distribution (p > 0.05).
In MarketScan, female patients with HS outnumbered male patients by nearly 5: 1, making up 82.4% of the patients. MarketScan Medicaid patients overall are 58.4% female; thus, HS patients are more than three times as likely to be female as MarketScan patients in general. Considering the NAMCS data, patients with HS on Medicaid were only 49% female, while those with a private insurance were 63% female and those on Medicare were 88% female.
Taking into account race and ethnicity, NAMCS patients with HS were 78.0% white, 17.5% black or African American, and 4.5% of unknown race ( fig. 5 ). An estimated 4.9% were Hispanic or Latino of any race. Based on the 2000 Census estimates for the population, African Americans made slightly more than 50% more visits per 100,000 population than non-Hispanic Whites, while Hispanics made about half as many as non-Hispanic Whites ( table 7 ) . The difference in prevalence between Whites and African Americans may be greater than this, since African Americans make significantly fewer visits to dermatologists than Whites [5] . All medications comprising more than 5% of the total are listed. These medications represent all claims made after the first diagnosis of HS. HCL = Hydrochloride. fig. 6 ) were 45.6% non-Hispanic white, 47.3% black, 0.8% Hispanic, and 6.2% other races. This distribution reflects the general racial and ethnic distribution of the Medicaid population studied in MarketScan data, which is 52.2% non-Hispanic White, 31.2% Black, 4.6% Hispanic, and 12.0% other races. The ratio of blacks to whites is 1.74 times as high for HS patients compared to MarketScan patients in general.
In the NAMCS, HS patients were mostly young adults, with the greatest number of visits by patients in their 30s, followed by those in their 20s ( fig. 7 ) . These age groups accounted for about 60% of all HS visits. There was no statistically significant trend over time in average age (p > 0.05). In MarketScan, the greatest number of patients were in their 20s, followed closely by those in their 30s ( fig. 8 ) , with a steady decline across the older groups. In MarketScan, we used the age at first HS diagnosis, which may have contributed to MarketScan patients being somewhat younger.
Physicians of several specialties commonly saw HS patients in the NAMCS ( fig. 9 Visits 0 -9 1 0 -1 9 2 0 -2 9 3 0 -3 9 4 0 -4 9 5 0 -5 9 6 0 -6 9 7 0 -7 9
Color version available online year. General surgeons managed about 2 cases per physician per year, while the average general and family physician managed 0.5 cases. It appears that while dermatologists have somewhat more experience, no specialty has a great deal of experience treating this condition.
Discussion
The number of HS visits was quite low, considering a reported prevalence of 1%, or as much as 4% for the peak age group, in the literature [1] . Recent estimates based on nationally representative data by McMillan [6] and Cosmatos et al. [7] have challenged the previous estimates and suggest that the prevalence may be significantly lower.
McMillan speculates that the high prevalence previously reported is likely due to a self-report questionnaire with relatively low specificity, causing as much as 94% of identified cases to be false positives [6] . A local populationbased study of the incidence in Olmsted County, Minn., USA, also supported the idea that HS is rather rare [8] .
With an annual estimate from the NAMCS of 164,000 visits per year, a maximum of around 0.06% of the population is being treated at any given time. It may be that the prevalence is higher than the NAMCS would suggest, but many sufferers are not getting any treatment. Alternatively, cases of HS may be getting coded as something other than 705.83, or they may be misdiagnosed.
The data do support the idea that the typical HS patient is a female in her 20s or 30s, who is likely to be African American. This group may suffer from a particularly large quality of life impact from HS symptoms and should welcome new treatment options. The demographics also underscore the importance of availability of HS treatments that are safe for women who may become pregnant. Treatments such as acitretin and methotrexate are teratogenic or fetotoxic, but biologics are relatively safe during pregnancy (category B) and may have a good chance to become commonly used [9] .
Limitations of the NAMCS include the fact that it includes only outpatient visits to nonfederally employed providers and does not permit following individual patients over time. The standard unit of analysis is the patient visit. The severity of the disease and the body site are not recorded in the NAMCS, except insofar as the body site may occasionally be inferred from the patient's reason for visit. In patients with multiple diagnoses, it is not always possible to determine which medication was prescribed to treat which condition. Nevertheless, the extensive information gathered on each visit allows for the 
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Color version available online Fig. 9 . NAMCS patient visits for HS by physician specialty. The patients were about equally likely to see a general or family physician, general surgeon, or dermatologist. 73 assessment of demographics, differences between the experiences of particular groups, and trends over time.
The data seem to suggest that systemic treatments, other than antibiotics and pain medications, are rarely used at present. Some isotretinoin is used, but isotretinoin is no longer believed to be effective for HS. The available Mar-ketScan data only go up to 2007, and the published trials of biologics for HS are all from 2010 or later, so it may be that the current datasets do not capture the most recent changes in practice. However, the fact that the average MarketScan patient with HS got approximately 12 different medications seems to suggest that existing treatments have not been very effective. Therefore, although the HS population appears relatively small, there may be a high demand for data on the safety and efficacy of biologics for treating the disease in this population.
